| Similar Articles |
|---|
 |
The Motley Fool
May 31, 2007
Billy Fisher |
Not Seeing 20/20 at Advanced Medical Optics The company recalls a contact lens solution that might be linked to a rare infection. Investors, take note.   |
The Motley Fool
May 23, 2007
Matt Koppenheffer |
Dueling Fools: Private Equity Bull Is the head-on private equity assault on the public markets good for investors? |
The Motley Fool
July 5, 2005
Brian Gorman |
Bausch & Lomb Eyes China The firm's latest purchase will add geographic diversity to its pharmaceutical business. Investors, take note. |
The Motley Fool
April 22, 2004
Brian Gorman |
Bausch & Lomb Delivers The 150-year-old eye-care company's sales aren't sizzling, but its profitability is improving. |
Chemistry World
July 30, 2013
Emma Stoye |
Thousands face job cuts after Valeant's Bausch buyout Canadian pharmaceutical company Valeant plans to lay off up to 2700 staff to help finance its $8.7 billion acquisition of US eye health specialist Bausch & Lomb. |
The Motley Fool
April 11, 2006
Rick Aristotle Munarriz |
Bausch & Lomb Sees Eye to Ay The contact lens specialist gets tripped up over its potentially infected ReNu brand. Bausch & Lomb's stock took a 9% hit in after-hours trading on the news. |
The Motley Fool
July 9, 2007
S.J. Caplan |
There WILL Be a Quiz: Weekly Markets Recap Takeover news was front and center during the shortened trading week. Have you been paying attention? Find out with our capital markets roundup and investors' quiz. |
The Motley Fool
April 19, 2005
Stephen D. Simpson |
Do The Eyes Have It for Bausch & Lomb? New product launches and extensions coupled with improving margins should boost results. Investors, take note. |
InternetNews
November 11, 2004
Colin C. Haley |
Report: Telecordia to be Bought for $1.3B The telecom software maker is reportedly close to being sold to two private-equity firms. |
The Motley Fool
July 26, 2005
Gardner & Mann |
For Shame, Warburg Pincus What transpired as a result of misplaced priorities among these board members who are partners at private equity firm Warburg Pincus is a deal that is substantially underpriced based on Transkaryotic's fundamentals. |
BusinessWeek
March 19, 2007
Emily Thornton |
Private Equity Goes Public Firms like KKR are buying stakes in public companies and pushing, gently, for change. |
The Motley Fool
October 27, 2005
Brian Gorman |
Bausch & Lomb's Cloudy Quarter An accounting scandal at a Brazilian subsidiary clouded third-quarter results, but the underlying business still looks good. Investors, take note. |
The Motley Fool
August 7, 2006
Stephen D. Simpson |
Advanced Medical Optics Still a Little Bloodshot This eye-care stock has done relatively well despite some ongoing sales issues. |
The Motley Fool
June 7, 2006
Stephen D. Simpson |
Cooper's Bleary Performance Missteps in strategy and operations for the contact lens company are coming home to roost. As is almost always the case with turnarounds, this is an idea with above-average risk, so don't make the mistake of underestimating the odds that things could get even worse. |
The Motley Fool
October 14, 2009
Matt Koppenheffer |
Does This Really Spell Doom for the Market? Private equity giant Blackstone is selling investments; does that mean you should run for the hills? |
BusinessWeek
June 20, 2005
Manjeet Kripalani |
Private Equity Pours Into India A lucrative Warburg Pincus deal sends a signal to other firms: There's big money to be made in India. |
The Motley Fool
March 3, 2009
Brian Orelli |
Pfizer Eyes Generic Growth Two partnerships in one day? Oh my! |
The Motley Fool
July 25, 2006
Stephen D. Simpson |
An Eye-Opening Quarter at Alcon Good news may have been overdue from the eye-care company, but the jubilation seems overdone. Investors, take note. |
The Motley Fool
July 25, 2011
Travis Hoium |
Bridgepoint Education Shares Plunged: What You Need to Know Investors in postsecondary education provider Bridgepoint Education had a rude awakening this morning when shares fell 12% to start the week. |
BusinessWeek
March 7, 2005
Gail Edmondson |
A Red Carpet For Americans As the pickings in the U.S. get lean, private equity groups have discovered that Europe is the land of opportunity. |
The Motley Fool
May 15, 2006
S.J. Caplan |
Bausch & Lomb Blinks Facing accounting and product woes, the eye-care company delays filing. Ratings agency Fitch has now lowered the company's credit ratings to just one notch above junk status. Investors, take note. |
The Motley Fool
October 12, 2006
Tim Hanson |
5 Turnaround Stocks These stocks are down, but not out: Bausch & Lomb... Compucredit... Intersections... Syneron Medical... etc. |
The Motley Fool
August 2, 2007
Tom Taulli |
China's Private Equity Dynasty? In the past, Chinese government regulation has prevented foreign private equity firms from buying companies, however, China now apparently recognizes the need for a domestic private equity industry. |
The Motley Fool
May 12, 2005
Tom Taulli |
ScanSoft's Nuanced Deal Wall Street doesn't like ScanSoft's merger with Nuance. But private equity firm Warburg Pincus does. |
The Motley Fool
November 2, 2005
Stephen D. Simpson |
AMO Focuses on the Giants Advanced Medical Optics sets its sights on the big players in eye care. Will David be able to take on the Goliaths? Investors, take note. |
The Motley Fool
December 16, 2004
Tom Taulli |
IPOs Come Up Aces Las Vegas Sands is not the only game in town this week. |
The Motley Fool
May 1, 2006
Stephen D. Simpson |
Alcon Still Not Living Up to Valuation Though this is a very solid medical technology company, its valuation still looks too high. |
The Motley Fool
August 19, 2005
Tim Beyers |
Baby Breaker Birth Announcements We track the week in private equity in search of investments of the future: In China: Microelectronics... Onewave Technologies... VeriSilicon Holdings... SmartPay... Kona Grill... |
